| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-05-11 16:37:25 UTC |
|---|
| Updated at | 2022-05-11 16:37:25 UTC |
|---|
| NP-MRD ID | NP0087015 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | 6-Keto-prostaglandin F1a |
|---|
| Description | 6-Keto-prostaglandin F1a, also known as 6-keto-PGF1a or 6-oxo-PGF1alpha, belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. Thus, 6-keto-prostaglandin F1A is considered to be an eicosanoid lipid molecule. 6-Keto-prostaglandin F1a is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. 6-Keto-prostaglandin F1a was first documented in 1983 (PMID: 6589104). In humans, 6-keto-prostaglandin F1A is involved in mefenamic acid action pathway (PMID: 11871383) (PMID: 9223652) (PMID: 12959636) (PMID: 9831332). |
|---|
| Structure | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O InChI=1S/C20H34O6/c1-2-3-4-7-14(21)10-11-16-17(19(24)13-18(16)23)12-15(22)8-5-6-9-20(25)26/h10-11,14,16-19,21,23-24H,2-9,12-13H2,1H3,(H,25,26)/b11-10+/t14-,16+,17+,18+,19-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 6-Keto-PGF1a | ChEBI | | 6-Keto-PGF1alpha | ChEBI | | 6-Keto-prostaglandin F1alpha | ChEBI | | 6-Ketoprostaglandin F1alpha | ChEBI | | 6-oxo-PGF1alpha | ChEBI | | 6-oxo-Prostaglandin F1alpha | ChEBI | | 6-Keto-PGF1α | Generator | | 6-Keto-prostaglandin F1α | Generator | | 6-Ketoprostaglandin F1a | Generator | | 6-Ketoprostaglandin F1α | Generator | | 6-oxo-PGF1a | Generator | | 6-oxo-PGF1Α | Generator | | 6-oxo-Prostaglandin F1a | Generator | | 6-oxo-Prostaglandin F1α | Generator | | 6-Oxoprostaglandin F1alpha | HMDB | | 6-Oxoprostaglandin F1a | HMDB | | 6-Oxoprostaglandin F1α | HMDB | | 6-Ketoprostaglandin F1 alpha | HMDB | | 6-oxo-9S,11R,15S-Trihydroxy-13E-prostenoate | HMDB | | 6-oxo-9S,11R,15S-Trihydroxy-13E-prostenoic acid | HMDB | | 6 Keto PGF1 alpha | HMDB | | 6-oxo-PGF1 alpha | HMDB | | 6-Oxoprostaglandin F1 alpha | HMDB | | F1 alpha, 6-Ketoprostaglandin | HMDB | | alpha, 6-Ketoprostaglandin F1 | HMDB | | alpha, 6-oxo-PGF1 | HMDB | | alpha, 6-Oxoprostaglandin F1 | HMDB | | 6 oxo PGF1 alpha | HMDB | | 6 Oxoprostaglandin F1 alpha | HMDB | | 6-Keto-PGF1 alpha | HMDB | | F1 alpha, 6-Oxoprostaglandin | HMDB | | alpha, 6-Keto-PGF1 | HMDB | | 6 Ketoprostaglandin F1 alpha | HMDB |
|
|---|
| Chemical Formula | C20H34O6 |
|---|
| Average Mass | 370.4804 Da |
|---|
| Monoisotopic Mass | 370.23554 Da |
|---|
| IUPAC Name | 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoic acid |
|---|
| Traditional Name | 6 keto PGF1 α |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O |
|---|
| InChI Identifier | InChI=1S/C20H34O6/c1-2-3-4-7-14(21)10-11-16-17(19(24)13-18(16)23)12-15(22)8-5-6-9-20(25)26/h10-11,14,16-19,21,23-24H,2-9,12-13H2,1H3,(H,25,26)/b11-10+/t14-,16+,17+,18+,19-/m0/s1 |
|---|
| InChI Key | KFGOFTHODYBSGM-ZUNNJUQCSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Fatty Acyls |
|---|
| Sub Class | Eicosanoids |
|---|
| Direct Parent | Prostaglandins and related compounds |
|---|
| Alternative Parents | |
|---|
| Substituents | - Prostaglandin skeleton
- Long-chain fatty acid
- Fatty alcohol
- Hydroxy fatty acid
- Keto fatty acid
- Cyclopentanol
- Cyclic alcohol
- Secondary alcohol
- Ketone
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic oxide
- Organic oxygen compound
- Alcohol
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic homomonocyclic compound
|
|---|
| Molecular Framework | Aliphatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - de la Cruz JP, Guerrero A, Gonzalez-Correa JA, Marquez E, Nacle I, Sanchez de la Cuesta F: Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans. Eur J Clin Pharmacol. 2002 Jan;57(11):775-80. doi: 10.1007/s00228-001-0391-8. [PubMed:11871383 ]
- Laitinen O, Seppala E, Nissila M, Vapaatalo H: Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis. Clin Rheumatol. 1983 Dec;2(4):401-6. doi: 10.1007/BF02041562. [PubMed:6589104 ]
- Jawerbaum A, Rosello Catafau J, Gonzalez ET, Novaro V, Gomez G, Gelpi E, Gimeno MA: Eicosanoid production by placental and amnion tissues from control and non-insulin-dependent diabetic rats. Influence of oxytocin in the incubating medium. Prostaglandins Leukot Essent Fatty Acids. 1997 Jun;56(6):425-9. doi: 10.1016/s0952-3278(97)90594-9. [PubMed:9223652 ]
- Cerletti C, Dell'Elba G, Manarini S, Pecce R, Di Castelnuovo A, Scorpiglione N, Feliziani V, de Gaetano G: Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet. 2003;42(12):1059-70. doi: 10.2165/00003088-200342120-00004. [PubMed:12959636 ]
- Katori M, Majima M, Harada Y: Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Inflamm Res. 1998 Oct;47 Suppl 2:S107-11. doi: 10.1007/s000110050293. [PubMed:9831332 ]
|
|---|